drugset / Trial / NCT00700635

Dose Comparison Study of Menactra® in US Children

NCT00700635

Phase 2 Completed 333 enrolled Sanofi Pasteur, a Sanofi Company
Non-randomizedParallel-groupOpen-labelPrevention

Summary

To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.

Timeline

Start
2008-06
Primary completion
2009-05
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Menactra Vaccine 0.5 ml Intramuscular